Amgen is making a major addition to its research leadership, bringing former Novartis research executive Jay Bradner into a top role while shifting current R&D chief David Reese to lead technology and AI.
Bradner left his role last year as head of Novartis’ research arm, the Novartis Institutes for BioMedical Research, following a major shakeup at the pharma company. He was succeeded by Fiona Marshall, who was previously Merck’s discovery and translational medicine head. For a year, Bradner returned to being a clinician at the Dana-Farber Cancer Institute and Brigham & Women’s Hospital. Before joining Novartis nearly eight years ago, Bradner had been a well-known physician-scientist at Dana-Farber and Harvard Medical School.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.